546090-57-7

Basic information

• Product Name: 2-cyano-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)acetamide
• Synonyms: 2-cyano-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)acetamide;2-cyano-N-[4-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]phenyl]acetamide;2-cyano-N-[4-[(3,4-dimethyl-1,2-oxazol-5-yl)sulfamoyl]phenyl]ethanamide;2-cyano-N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]acetamide;2-cyano-N-[4-[(3,4-dimethylisoxazol-5-yl)sulfamoyl]phenyl]acetamide;IVK/9357814
• CAS NO: 546090-57-7
• Molecular Formula: C₁₄H₁₄N₄O₄S
• Molecular Weight: 334.35036
• Mol File: 546090-57-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-cyano-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-cyano-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)acetamide(546090-57-7)
• EPA Substance Registry System: 2-cyano-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)acetamide(546090-57-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 546090-57-7(Hazardous Substances Data)

Upstream product

• 127-69-5 sulfisoxazole 
• 36140-83-7 1-cyanoacetyl-3,5-dimethylpyrazole 

Downstream Products

• 1621153-31-8 2-cyano-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)-2-[(4-methoxyphenyl)hydrazono]acetamide 
• 1621153-32-9 2-cyano-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)-2-[(4-ethoxyphenyl)hydrazono]acetamide 
• 1621153-37-4 4-[3,5-dicyano-6-mercapto-4-(4-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide 
• 1621153-38-5 4-[3,5-dicyano-6-mercapto-4-(4-chlorophenyl)-2-oxopyridin-1(2H)-yl]-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide 
• 1621153-39-6 4-[3,5-dicyano-4-(2-furyl)-6-mercapto-2-oxopyridin-1(2H)-yl]-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide 
• 1621153-40-9 4-[3,5-dicyano-4-(3-pyridyl)-6-mercapto-2-oxopyridin-1(2H)-yl]-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide 
• 1621153-21-6 4-amino-5-cyano-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)-2-(phenylamino)thiophene-3-carboxamide 
• 1621153-35-2 4-(3-cyano-4,6-dimethyl-2-oxopyridin-1(2H)-yl)-N-(3,4-dimethyl-isoxazol-5-yl)benzenesulfonamide 
• 1621153-36-3 4-[6-amino-3,5-dicyano-4-(4-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide 
• 1621153-16-9 5-acetyl-4-amino-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)-2-(methylamino)thiophene-3-carboxamide 
• 1621153-17-0 5-acetyl-4-amino-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)-2-(ethylamino)thiophene-3-carboxamide 
• 1621153-18-1 5-acetyl-2-(allylamino)-4-amino-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino] sulfonyl}phenyl)thiophene-3-carboxamide 
• 1621153-19-2 5-acetyl-2-(adamantylamino)-4-amino-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)thiophene-3-carboxamide 
• 1621153-26-1 5-amino-N-(4-{[(3,4-dimethylisoxazol-5-yl)amino]sulfonyl}phenyl)-3-(4-methoxyphenyl)-1H-pyrazole-4-carboxamide 

Relevant articles and documents

New acrylamide-sulfisoxazole conjugates as dihydropteroate synthase inhibitors

New functionalized acrylamide derivatives bearing sulfisoxazole moiety were designed to target bacterial dihydropteroate synthase (DHPS). The in vitro antimicrobial activities of these compounds were assessed. The E-configuration of compound 5b was proved

Novel hydrazide-hydrazone and amide substituted coumarin derivatives: Synthesis, cytotoxicity screening, microarray, radiolabeling and in vivo pharmacokinetic studies

The current work presents the synthesis and biological evaluation of new series of coumarin hydrazide-hydrazone derivatives that showed in vitro broad spectrum antitumor activities against resistant pancreatic carcinoma (Panc-1), hepatocellular carcinoma (HepG2) and leukemia (CCRF) cell lines using doxorubicin as reference standard. Bromocoumarin hydrazide-hydrazone derivative (BCHHD) 11b showed excellent anticancer activity against all tested cancer cell lines. Enzyme assays showed that BCHHD 11b induced apoptosis due to activation of caspases 3/7. Moreover, 11b inhibited GST and CYP3A4 in a dose dependent manner and the induced cell death could be attributed to metabolic inhibition. Moreover, 11b microarray analysis showed significant up- and down-regulation of many genes in the treated cells related to apoptosis, cell cycle, tumor growth and suppressor genes. All of the above presents BCHHD 11b as a potent anticancer agent able to overcome drug resistance. In addition, compound 11b was able to serve as a chemical carrier for 99mTc and the in vivo biodistribution study of 99mTc-11b complex revealed a remarkable targeting ability of 99mTc into solid tumor showing that 99mTc-11b might be used as a promising radiopharmaceutical imaging agent for cancer.